A revised 1.6 Å structure of the GTPase domain of the Parkinson's disease-associated protein LRRK2 provides insights into mechanisms.

Chun-Xiang Wu^{1,2*}, Jingling Liao^{1,2,3*}, Yangshin Park^{1,2}, Neo C. Hoang^{1,2}, Victoria A. Engel^{1,2}, Li Wan^{1,2}, Misook Oh^{1,2}, Ruslan Sanishvili⁴, Yuichiro Takagi¹, Steven M. Johnson¹, Mu Wang^{1,5}, Mark Federici⁶, R. Jeremy Nichols⁷, Alexandra Beilina⁸, Xylena Reed⁸, Mark R. Cookson⁸, and Quyen Q. Hoang^{1,2,9}

¹Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, ²The Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, ³Department of Public Health, Wuhan University of Science and Technology School of Medicine, 43005 Wuhan, China, ⁴X-ray Science Division, Argonne National Laboratory, Argonne, IL 60439, ⁵Department of Biological Sciences, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu 215123 China, ⁶ThermoFisher Scientific, Carlsbad, CA 92087, ⁷Department of Pathology, Stanford University, Stanford, CA 94305, ⁸Laboratory of Neurogenetics, National Institute of Health, Bethesda, MD 20892, ⁹Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202.

*These authors contributed equally to this work

Submitted to <journal>

Leucine-rich repeat kinase 2 (LRRK2) is a large 286 kDa multi-domain protein whose mutation is a common cause of Parkinson's disease (PD). One of the common sites of familial PD-associated mutations occurs at residue Arg-1441 in the GTPase domain of LRRK2. Previously, we reported that the PD-associated mutation R1441H impairs the catalytic activity of the GTPase domain thereby traps it in a persistently "on" state. More recently, we reported that the GTPase domain of LRRK2 exists in a dynamic dimer-monomer equilibrium where GTP binding shifts it to the monomeric conformation while GDP binding shifts it back to the dimeric state. We also reported that all of the PD-associated mutations at Arg-1441, including R1441H, R1441C, and R1441G, impair the nucleotide-dependent dimer-monomer conformational dynamics of the GTPase domain. However, the mechanism of this nucleotide-dependent conformational dynamics and how it is impaired by the mutations at residue Arg-1441 remained unclear. Here, we report a 1.6 Å crystal structure of the GTPase domain of LRRK2. Our structure has revealed a dynamic switch region that can be differentially regulated by GTP and GDP binding. This nucleotide-dependent regulation is impaired when residue Arg-1441 is substituted with the PD-associated mutations due to the loss of its exquisite interactions consisting of two hydrogen bonds and a π -stacking interaction at the dimer interface.

LRRK2 | Parkinson's disease | GTPase | Kinase | X-ray crystallography

Abbreviations: LRRK2, Leucine-Rich Repeat Kinase 2; ROC, Ras of complex proteins; COR, C-terminal of ROC

Significance Statement

Mutations in LRRK2 are associated with familial Parkinson's disease, so understanding its mechanism of actions and how they are changed by the disease-associated mutations is important for developing therapeutic strategies. This paper describes an atomic structure of the G-domain of LRRK2 revealing that the conformational dynamics of the switch regions are potentially important for its normal function. It further shows that a disease-associated mutation could lock the G domain in a persistently active-like conformation, thus perturbing its normal function.

Mutation in the Leucine-Rich Repeat Kinase 2 (LRRK2) is a common cause of familial Parkinson's disease (PD)(1-5). LRRK2 is a large (2,527 amino acids) multi-domain enzyme consisting of 7 putative domains(2), including a HEAT repeat, an Ankyrin repeat, a Leucine-rich repeat (LRR), a Ras-like GTPase domain called 'Ras of complex proteins' (ROC), a unique domain called C-terminal of ROC (COR), a kinase domain (Kin), and a C-terminal WD40 repeat(6). The most common PD-associated mutations (G2019S and R1441G/C/H) are found in the central three domains, ROC-COR-Kin, that constitutes the catalytic core of the protein. Residue Gly-2019 is predicted to reside in the activation loop of the kinase domain, and the G2019S mutant has been shown to have higher kinase activity than that of the wild-type enzyme(7, 8). Thus, the glycine to serine substitution mutation, which introduces a hydroxyl group, potentially mimics the activated state of the kinase.

The effects of the PD-associated mutations in the ROC domain at residue Arg-1441 (R1441G/C/H) have been less understood. Several studies have shown that GTP binding to the ROC domain up regulates LRRK2 kinase activity(9, 10) and, conversely, inhibition of ROC decreases kinase activity(9-13), thus indicating that the ROC domain could modulate the activity of the kinase domain. Moreover, the PD-associated mutations at Arg-1441 have been shown to also result in a higher LRRK2 kinase activity than that of the wild-type(8, 9, 12), suggesting that residue Arg-1441 is vital for the normal functioning of ROC. Indeed, we recently engineered a stable construct of ROC (ROC_{ext}) and showed that the R1441H mutation perturbs the hydrolytic conversion of GTP to GDP, thereby prolonging the GTP-bound "on" state of ROC(14). Subsequently, we showed that GTP-binding drives dimeric ROC_{ext} disassembly into monomers and GDP-binding oppositely shifts the equilibrium back to dimers(15). Moreover, we showed that all the PD-associated mutations at Arg-1441, as well as N1437H, impair the dimer-monomer dynamics of ROC_{ext}(15, 16).

The mystery remains as to how residue Arg-1441 affects the catalytic activity of ROC and its nucleotide-dependent conformational dynamics given that the position 1441 resides outside of the regions known to be involved in the activity of GTPases, including the nucleotide-binding site, active-site, and the switch regions. Here, we show a high-resolution crystal structure of ROC_{ext} revealing the role of residue R1441 in the stability of the dimeric conformation and providing insights into how the Parkinson's disease-associated mutations R1441G/C/H impair its conformational dynamics.

Figure 1. Structure of ROC_{ext}. **a**) Crystal structure of ROC dimer (1.6 Å) shown in semi-transparent surface and ribbon presentations. Chain A is colored orange and chain B colored teal. The dotted lines outline the areas presented in **b**) and **c**). **b**) Enlarged view of the area highlighted in top panel of **a**) showing extensive hydrogen bonding at the dimer interface. **c**) Enlarged view of the area highlighted in bottom panel of **a**) showing a hydrophobic patch at the dimer interface, which is capped at both ends by residue R1441. **d**) and **e**) ribbon presentation showing signature structural features of a small GTPase, including Switch I (magenta), InterSwitch (blue), and Switch II (teal). GDP is shown as rod-and-ball model. **f**) and **g**) electron-density map (2FoFc) of the Switch regions and GDP, respectively, contoured at 1.0 σ .

Results and Discussion

The architecture of the ROC domain of LRRK2

While a structure of the ROC domain of LRRK2 has been determined a decade ago (PDB ID: 2ZEJ)(17), that structure has been inconsistent with subsequent biochemical and biophysical observations. For example, the 2ZEJ structure showed an obligate dimer with an active-site composed of one half from each protomer; however, biochemical studies have demonstrated that ROC dynamically interconverts between its dimeric and monomeric conformations and that the monomers are catalytically active(14, 15). Thus, the examination of the 2ZEJ structure did not provide us with the insights that we sought to understand the conformational dynamics ROC and the mechanisms of the PD-associated mutations. We attempted to glean these insights from structures of the homologous protein Roco from *C. tepidum*(18, 19); however, we found significant differences between the ROC domain of human LRRK2 (HsROC) and that of *C. tepidum* Roco (CtROC). For example, the PD-associated residues in HsROC are not conserved in CtROC, including residue R1441 in HsROC; therefore, the potential biochemical and structural effects of the PD-associated mutations cannot be inferred directly from the CtROC structures. Due to these reasons, we set out to determine the structure of the human ROC_{ext} construct to examine the structural bases for the biochemical and conformational dynamics we observed(14, 15, 20).

We have determined a crystal structure of ROC_{ext} to 1.6 Å resolution using X-ray crystallography. The initial electron density map was calculated using a combination of phases determined with SHARP(21) using single-wavelength anomalous dispersion of selenomethionine (SeM-SAD) from crystals of selenomethionine-substituted proteins, which diffracted to 3.7 Å, and those calculated by the molecular replacement (MR) method using the program Phenix(22) with a 1.9 Å native dataset. To obtain a better crystal quality and higher resolution, we performed “surface engineering” by substituting two surface lysine residues for alanine (K1460A and K1463A). The surface engineered mutant (KA) retained wild-type activity and structure (Fig. S1). The data from crystals of the surface-engineered protein extended to 1.6 Å resolution and were used for model building and refinement. A contiguous polypeptide chain ranging from residues 1331 to 1518, which nearly encompassed the entire ROC_{ext} construct (1329-1520), was unambiguously fitted into the electron density and refined to convergence with R-factor and R-free of 14% and 16%, respectively (Sup. Table 1).

The asymmetric unit (AU) consists of a homodimeric structure of ROC_{ext} related by 2-fold symmetry. The interactions at the dimer

interface are extensive, burying 6461 Å² of surface area (Fig. 1a-c). The intermolecular interactions are mediated chiefly by the structures that are known as Switch I, Switch II, and the InterSwitch, herein collectively referred to as the Switch regions (Fig. 1b-e). The dimeric interface is unusual in that the InterSwitch is flipped open and inserted into its dimeric partner *in trans* with both monomers wrapped around each other like a pretzel (Fig. 1a). This dimeric conformation has been previously observed in *M. Musculus* Rab27b, which showed a similar extended InterSwitch structure that reaches across the homodimeric interface(23). Apo Rab27b exists in solution as a monomer with its InterSwitch extended, however, upon binding to its effector Slac2-a it folds into a typical G-protein conformation with a retracted InterSwitch and adopting a conformation similar to that of the typical Ras-family of G-proteins(24).

The tertiary structure of ROC_{ext} is very similar to other G-proteins in that it consists of all the characteristic structural elements, including Switch I, Switch II, P-loop, and the G-binding motifs (Fig. 1d-g). The Switch I and Switch II regions of ROC_{ext} are distal from the GDP-binding site, as they can also occur in GDP-bound Ras-like GTPases. However, in contrast to Ras, the InterSwitch of ROC_{ext}, which is flanked by the Switch I and Switch II, is flipped outward and protrude away from the protein core - like a ‘thumbs-up’ hand gesture (Fig. 1d,e). A well-defined molecule of GDP is bound in a location similar to the nucleotide-binding site in Ras (Fig. 1g).

Comparison of ROC_{ext} with the previously reported ROC structure

Superposition of the structure of ROC_{ext} with 2ZEJ revealed two significantly different structures (RMSD = 10.4 Å²). A large portion of the N-terminus of 2ZEJ (residues 1335-1397) consisting of β1, H1, β2, and β3 are flipped outward and detached from the rest of the protein, in effect, breaking the G-domain into two distinct halves with the N- and C-terminus separated from each other (Fig. 2a). Removing the non-overlapping moieties, β1 and H1, from the structural superposition resulted in two structures that are nearly identical (RMSD = 0.4 Å²). Close inspection revealed that the β1 and H1 moieties in chain A of 2ZEJ occupy precisely the same locations of the β1 and H1 of chain B in our ROC_{ext} structure (Fig. 2b), thus suggesting that the structural differences might be simply due to the difference in chain assignment of β1 and H1. Indeed, superposition of the two structures as dimers showed nearly identical structures (RMSD = 0.3 Å²). Inspection of the electron-density map of the 2ZEJ structure revealed that the junctions between H1 and β2, where the Switch I would reside, lacked interpretable density (Fig. S2, S3); thus rendering the task of assigning the chain ID for the H1 and β2 segment ambiguous. Since our electron-density map

Figure 2. Superposition of ROC_{ext} with 2ZEJ. **a)** Structure of ROC_{ext} (gold) superimposed with the ROC structure in the literature, 2ZEJ, (blue). The equivalent structural elements that are located in different locations in the two structures are outlined with dashed lines. **b)** Superposition of ROC_{ext} dimer (gold and red) with 2ZEJ (teal and blue), showing overlap of all atomic positions of 2ZEJ with those of ROC_{ext}. Structural elements in ROC_{ext} missing in 2ZEJ are highlighted with grey dashed lines.

unambiguously defined a contiguous polypeptide chain, we propose that the ROC_{ext} presented herein represents a revised structural model. Indeed, when the chain ID assignments for β 1 and H1 in 2ZEJ were swapped (A to B and vice versa), the resulting structure looked nearly identical to our ROC_{ext} (Fig. S4).

Comparison of human ROC with *C. tepidum* Roco

Because of the difficulty in obtaining sufficient quantity of LRRK2 amenable for detailed investigations, insights into its structure and function have been inferred from the amoeba and bacterial homologs (18, 25). Notably, much insight into the ROC domain of LRRK2 (HsROC) has been inferred from a ROC structure of the bacterium *C. tepidum* Roco protein (CtROC) (PDB ID: 3DPU, 6HLU). For example, the mechanism of GTPase hydrolysis of HsROC has been proposed based on the studies of CtROC, where the activation occurs upon an arginine finger exchange in the active-site mediated by homodimerization (known as the GTPase activation by dimerization model or GAD) (18)(26). However, we have recently shown that ROC_{ext} is catalytically active as a monomer, suggesting that the mechanism of HsROC might be different from that of CtROC. To assess the similarity and differences between CtROC and ROC_{ext}, we superimposed the two structures. Although they share low sequence identity (25%), the overall architecture of the two structures are remarkably similar (RMSD = 2.2 Å²) (Fig. 3a). Nevertheless, the superimposed structures did reveal several important differences: firstly, the ROC-ROC dimeric interface of CtROC contains the P-loop, whereas the dimeric interface of ROC_{ext} comprises of the Switch regions (Fig. 3b). Note that neither the dimerization mode of CtROC nor ROC_{ext} supports a GAD mechanism of GTPase activation, as there is no arginine finger-exchange occurring in the active sites. Second, the disease-associated residues R1441, N1437, and R1398 in HsROC structurally aligned with residues Y558, H554, and Q519 of CtROC,

respectively. The difference in amino acids at these positions is important in that the substitution of residue Arg1441 in HsROC for Tyr found in the equivalent position in CtROC, and residue N1437 in HsROC for His of CtROC both resulted in impairment of the conformational dynamics of ROC_{ext} (15, 16) (Fig. 3c). Finally, the arginine residue R543 of CtROC that is proposed to serve as the GTPase-activating arginine finger is structurally equivalent to residue S1422 of HsROC (Fig. 3d). While the studies of CtRoco have been instrumental for the understanding of the overall architecture of ROC-COR, these structural differences suggest caution in deducing the structure and mechanisms of HsROC from the observations of CtROC.

The crystal structure of ROC_{ext} represents its in-solution dimeric conformation

As reported previously, ROC_{ext} exists in solution in a dynamic monomer-dimer equilibrium. To investigate whether the dimer in solution is the same as the dimer in crystal, we introduced an intermolecular disulfide bond between two residues that are in close proximity of each other, but each residing on opposite side of the dimer interface of the crystal dimer. This disulfide bond links *in trans* the helix H2 of one protomer to the helix H4 of the other protomer (residues R1398C and W1434C) (Fig. 4a, Fig. S5a, b).

The resulting disulfide-stabilized construct (S-S) formed both monomeric and dimeric conformations reminiscent of the WT (Fig. S6 & S7). Circular dichroism (CD) spectroscopy showed no significant structural differences between the S-S mutant and the WT dimers (Fig. 4b). However, the S-S dimer loses the ability to convert to monomers upon nucleotide binding under disulfide bond-stabilizing oxidative conditions, but in disulfide bond-breaking reducing conditions, its propensity to form monomers is restored to the wild-type level (Fig. 4c). Likewise, the S-S dimer is more thermostable than the WT under oxidizing conditions, but returned

Figure 3. Comparison with the structure of CtROC. a) Superposition of ROC_{ext} dimer (gold and red) with CtROC (green), showing that the two structures overlap well, other than the turn/loop of the InterSwitch between b1 and b2 (highlighted in grey dashed line). b) Superposition of A-chain of ROC_{ext} with A-chain of CtROC (6HLU), showing that the two structures form dimers via different interactions and surfaces. c) and d) Enlarged view of the superposition of ROC_{ext} with CtROC, showing the amino acid differences between the structures.

Figure 4. Engineered disulfide-stabilized ROC dimer. **a)** A calculated model of ROC dimer consisting of an engineered disulfide bond between residues 1398 and 1431 (S-S). **b)** CD spectrum showing similar profile between the S-S dimer and wild-type. **c)** Size-exclusion chromatography elution profiles showing that the S-S dimer has lost the ability to convert to dimer and then regains that capability when the cysteine residues are reduced with DTT. **d)** Thermofluor denaturation assay showing that the S-S dimer is more thermally stable than the wild-type, but reverts to wild-type melting temperature when reduced with DTT. **e)** Fluorescence polarization assay showing that the S-S dimer binds GDP with a similar affinity to wild-type.

to WT T_m upon reduction with DTT (Fig. 4d). Finally, the GDP-binding affinity of the S-S dimer is the same as that of the WT (Fig 4e).

Taken together, these results indicate that the *in crystallo* dimer is structurally the same as the dimer we observed in solution, and therefore, insights gleaned from the crystal structure would be reflective of the structure in solution.

Insights into the mechanism of ROC

Understanding the mechanism of the ROC domain of LRRK2 is important for understanding its overall function and for the development of mechanism-based therapeutic strategies. However, the current understanding of ROC has been mostly inferred from other well-characterized G-proteins. They all function as molecular switches that toggle between "on" and "off" upon binding to GTP or GDP, respectively. The binding of GTP typically causes the stabilization of two flexible structures, known as Switch I and Switch II, as they both interact electrostatically with the γ -phosphate of GTP. The ordering of the switch regions presents a surface for interacting with downstream effector proteins, and its disordering upon GTP hydrolysis (or exchanged for GDP) resets the molecular switch back to the "off" state(27-29). Indeed, the ROC domain of LRRK2 has been shown to possess some of these characteristics, including guanine nucleotide binding, GTP hydrolysis, and nucleotide-dependent conformational changes. However, ROC has also been shown to present several characteristics that do not fit precisely into the typical small G-protein model. For example, ROC always exist in tandem with a domain called C-terminal of ROC (COR) within a large protein, ROC remains active event when mutated to residues that would abolish the activity of the other Ras-family G-proteins, and its 'ability' to hydrolyze GTP is required for its activity but not the hydrolysis event itself per se(30). Although it is evident that the ROC domain of LRRK2 is a bona fide G-protein, these differences suggest that the mechanism of ROC might be different from that of the typical small G-proteins.

To gain insights into the mechanism of ROC, we examined the atomic structure of ROC_{ext} to glean the structural bases for its biochemical activities. We recently reported that ROC_{ext} exists in a dynamic monomer-dimer equilibrium and that GTP or GDP binding drives monomerization or dimerization, respectively(15). The structure of ROC_{ext} reveals that the dimeric configuration of ROC_{ext} is predominantly stabilized by five hydrogen bonds between β 3 in the InterSwitch of one protomer and β 1 in the core of the other and arranged parallel with respect to each other like a zipper (Fig 1b,c). The labile nature of these hydrogen bonds is well suited to provide the plasticity necessary for the 'zipping' and 'unzipping' in the interconversion between the dimeric and monomeric conformations.

Since we have only the GDP-bound structure, how the binding of GTP would drive the unzipping of the dimer is unclear. However, close examination of our ROC_{ext} structure revealed plausible clues. The residues flanking either side of the InterSwitch possess dihedral angles that are conformationally strained (ϕ , ψ angles of S1360 and Q1411 are -93°, -90° and -105°, 96°, respectively) and, as such, the stored energy in these hinge regions could potentially act as a set of spring-loaded hinges that provide the driving force for unzipping the dimer triggered by GTP binding. This led us to question how does GTP binding trigger the process of monomerization. The mechanism of GTP-induced conformational changes in small G-proteins involves the γ -phosphate group of GTP interacting with a threonine residue of Switch I and a glycine residue of Switch II. To investigate whether or not this occurs in ROC_{ext}, we examined the structure of ROC_{ext} to see if it consists of the essential γ -phosphate-interacting threonine and glycine. To do so, we built a homology model of GTP-bound conformation of ROC_{ext} by using a GTP-bound conformation of Ras (PDB ID: 6Q21) as a modeling template for the switch regions. Superposition of 6Q21 with the GTP-bound homology model of ROC_{ext} reveals that it does indeed consist of a threonine residue (T1368) in Switch I and a glycine residue (G1397) in Switch II located at practically the same locations as the γ -

phosphate-interacting residues, T35 and G60, respectively, of Ras (Fig. 5a,b and Fig. S8). The conservation of T1368 and G1397, both in primary and tertiary structures, with the corresponding γ -phosphate-interacting residues of Ras suggests that their interaction with the γ -phosphate of GTP could analogously trigger conformational changes of the Switch regions. We noted that GTP-binding to Ras triggers the ordering of the Switch I and Switch II; however, the structure of ROC_{ext} suggests that conformational changes in the two switches also necessitate a conformational change of the InterSwitch. This opens the possibility that the conformational changes of the InterSwitch might be involved in yet to be identified interactions analogous to Rab27b interaction with Slac2a(23, 24).

Biochemical and structural data, shown herein and in the literature, have sufficiently demonstrated that the ROC domain of LRRK2 forms an independently folded and functional unit; however, how it interacts intramolecularly with the other domains, especially the adjacent COR domain, remains unclear. To investigate this, we docked the dimeric form of ROC as found in our crystal structure, the monomer of our crystal structure, and the GTP-bound model of ROC (ROC-GTP) mentioned above, to the COR domain of the CtRoco protein (PDB ID: 6HLU)(18, 19). The crystal structure of ROC_{ext} showed significant clashes with the docked CtRoco COR domain. Even in the monomeric form, the Switch regions clashed with the CtRoco COR domain. However, the ROC-GTP monomeric model docked to the CtRoco COR domain well with no backbone clashes between the two domains, and the surface containing the Switch regions, especially the InterSwitch, interfaces with the COR domain with remarkable complementarity (Fig. 5c,d).

Taken together, the data suggest that the Switch regions of the ROC domain of LRRK2 interact directly with its COR domain and

that the nucleotide-dependent conformational changes of the Switch regions might modulate this interaction. However, more work is needed to validate the insights gleaned from the ROC-COR docking exercise.

Insights into the mechanism of disease-associated mutations

Several lines of evidence have shown that LRRK2 harboring the disease-associated mutation R1441C/G caused a reduction in GTPase activity(12, 14, 31-33) and GTP binding to the ROC domain modulates kinase activity(10, 13, 30). These data suggest that the GTPase activity of LRRK2 potentially regulates its kinase activity. Recently, we reported that, in addition to a reduction in GTPase activity, a common biochemical consequence of all three PD-associated mutant constructs, including R1441H, R1441G, and R1441C, is a loss of the monomer-dimer conformational dynamics that we observed in the wild-type protein(15).

To gain insights into how the PD-associated mutants led to a loss of ROC conformational dynamics, we examined the crystal structure of ROC_{ext}. The structure revealed that residue R1441 reaches across the dimer interface and interacts exquisitely with the opposing protomer (Fig. 1 and Fig. 6). The interaction consists of an arginine- π -stacking between R1441 and F1401. The strong π -stacking interaction with the phenyl ring of F1401 orients the plane of the R1441 guanidinium moiety such that its two ω -amines are ideally positioned for hydrogen-bonding with the backbone carbonyl oxygen of F1401 and sidechain hydroxyl of T1404 (Fig. 6b). This Arg-Phe π -stacking interaction is typically found in proteins where strong and malleable interactions occur(34), thus suggesting that residue R1441 might be essential for the stability and plasticity of ROC. In addition to the π -stacking, the sidechain of R1441 fits into the pocket between residues F1401 and T1404 with perfect Van der

Figure 5. Modeling of a monomeric form of ROC. a) and b) A model of monomeric GTP-bound ROC built based on the ROC_{ext} dimer and the switch regions of the structure of GppNHp-bound Ras (6q21), showing that ROC has all the structural elements and residues that are involved in the GTP-mediated conformational changes in Ras. c) and d) docking of GTP-bound ROC model to the COR domain of CtRoco (6HLU), showing the surface complementarity between the two structures.

Figure 6. Role of R1441 residue in conformational dynamics of ROC. a) and b) Enlarged view of the dimeric interface of ROC_{ext} around residue R1441 (rod-bond model). The electron-density (2FoFc at 1s) is shown as green mesh. c) SEC-MALS of the R1441K mutant form of ROC (blue line) compared to the WT dimer (black line) and WT monomer (black dotted line), showing that substituting arginine for lysine at position 1441 completely abolished dimerization. d) GTPase activity of R1441K (purple and blue) compared to WT (black), showing that the R1441K mutation impaired GTPase activity.

Waals complementarity (Fig. S9). Given the intricacy of the interactions and the tight complementarity involved, it appeared that no other natural amino acid would adequately substitute for the arginine at position 1441. To test this, we substituted R1441 for a relatively conserved amino acid, lysine, which preserved a positively charged amine and a long aliphatic sidechain. We found that the R1441K mutant adopted only the monomeric conformation and its activity was significantly reduced compared to that of the WT (Fig. 6d), suggesting that the intricate interactions conferred by the sidechain of residue R1441 is critical for maintaining a monomer-dimer equilibrium. This is also consistent with our recent report that substituting arginine1441 for a tyrosine resulted in a constitutive dimer(15). Now that the structure is available, we can see that a Tyr residue at position 1441 could form one hydrogen bond and a strong π - π -stacking interaction with phenylalanine 1401, which would be much less malleable than that of the WT.

Taken together, the structure is consistent with all the biochemical phenomena we observed in solution and further supports that R1441 is uniquely required for the normal nucleotide-dependent conformational dynamics of ROC_{ext}, and suggests that the PD-associated mutations at residue R1441 impair this process by disrupting the exquisite interactions endowed by the guanidinium moiety of the arginine residue.

Conclusion

Previous knowledge of the structure and function of the ROC domain of LRRK2 have been primarily inferred from a homologous protein CtRoco due to a lack of LRRK2 protein samples amenable for detailed biochemical and biophysical studies. At the onset of our investigation into the structure and function of ROC, we were uncertain whether the domain in isolation and in the absence of the other domains would fold and function independently. However, we now know that it does, in both accounts, which has enabled us to carry out detailed biochemical and biophysical studies(14-16), as well as herein described, to determine its atomic structure. Our studies unambiguously demonstrated that ROC_{ext} forms an independently folded domain that consists of structural features,

nucleotide binding properties, and enzymatic activity that are consistent with all the hallmarks of a Ras-like G-protein. It is noteworthy that the structure shows the N- and C-terminus of ROC_{ext} are in proximity of each other, as they occur in the other Ras-family G-proteins, and that they would be unperturbed by the conformational changes that occur in the processes of nucleotide exchange, hydrolysis activity, and monomer-dimer interconversions; therefore, should these activities occur in the full-length LRRK2, they can do so without requiring the movement of the flanking domains.

Although it is theoretically possible for ROC to form a homodimer in the context of the full-length LRRK2, it remains unclear whether or not that occurs, as there is insufficient data to make the determination. On the one hand, electron microscopy (EM) showed that full-length LRRK2 is dimeric and that the ROC domains are in close proximity for ROC-ROC interactions (although the dimeric interface is different from our structure) (35). On the other hand, size-exclusion chromatography of a ROC-COR tandem construct showed a dimeric structure, but a C-terminally truncated ROC-COR domain was mainly monomeric(36). However, the nucleotide status of these studies was unclear, and given the fact that ROC undergoes nucleotide-dependent conformational changes, the question of whether ROC forms a homodimer in the full-length LRRK2 remains to be elucidated. Given the fact that LRRK2 is a large protein it is likely that, in addition to ROC, the other domains are also involved in the dimerization of LRRK2. For example, the WD40 domain of LRRK2 forms a strong homodimer(37).

Based on the fact that the crystal structure showed that GDP-bound ROC_{ext} is homo-dimeric, SEC-MALS showed that GTP-bound ROC_{ext} is monomeric(15), and the docking models showed that ROC might interact with COR via the same surface in the homodimer interface, we imagined that homo-dimerization of the GDP-bound ROC would exclude its interaction with the COR domain and that its monomerization upon GTP binding might expose the surfaces available for hetero-dimerization of the two domains (Fig. 7).

with the program Phenix(22). Cycles of rebuilding and refinement using the programs Coot(41, 42), Phenix(22), and Refmac(43) at R_{work} and R_{free} of 13.5% and 15.8%, respectively.

ACKNOWLEDGMENTS

QQH acknowledges funding from the NIH (R01GM111639, R01GM115844) and the Michael J. Fox Foundation. YT acknowledges funding from the NIH (R01GM111695) and US National Science Foundation (MCB-1157688). This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (MRC). SMJ acknowledges funding from the NIH (R01GM120350). NCH acknowledges funding from the Travel and Learn program of the Indiana Association of Chinese-Americans (IACA). GM/CA@APS has been funded in whole or in part with Federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE)

Office of Science User Facility operated by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

Author Contribution

C.W. and J.L. designed and performed experiments as well as prepared the manuscript; Y.P., V.A.E., L.W., and M.O. created DNA constructs and other research agents as well as assisted with manuscript preparation; N.C.H performed the molecular dynamics simulations; R.S. assisted with X-ray data collection and analysis; S.M.J. assisted experimental design and manuscript preparation; M.W. assisted data acquisition and analysis, as well as manuscript preparation; A.B., X.R., and M.R.C. provided reagents and assisted manuscript preparation; M.F., Y.T., A.B, and J.N. provided key research reagents; Q.Q.H. designed experiments, analyzed data, and prepared the manuscript.

Structural Coordinates

Coordinates deposited to the Protein Data Bank (PDB ID: 6OJE and 6OJF).

Reference

1. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. *Nat Rev Neurosci* 11(12):791-797.
2. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, & Gallo KA (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. *Trends Neurosci* 29(5):286-293.
3. Giasson BI & Van Deerlin VM (2008) Mutations in LRRK2 as a cause of Parkinson's disease. *Neurosignals* 16(1):99-105.
4. Zimprich A, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 44(4):601-607.
5. Paisan-Ruiz C, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 44(4):595-600.
6. Liao J & Hoang QQ (2018) Roco Proteins and the Parkinson's Disease-Associated LRRK2. *Int J Mol Sci* 19(12).
7. Greggio E, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiology of Disease* 23(2):329-341.
8. West AB, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc Natl Acad Sci U S A* 102(46):16842-16847.
9. Guo L, et al. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. *Exp Cell Res* 313(16):3658-3670.
10. Ito G, et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. *Biochemistry* 46(5):1380-1388.
11. Oueslati A, Fournier M, & Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. *Prog Brain Res* 183:115-145.
12. West AB, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. *Hum Mol Genet* 16(2):223-232.
13. Biosa A, et al. (2013) GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. *Hum Mol Genet* 22(6):1140-1156.
14. Liao J, et al. (2014) Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain. *Proc Natl Acad Sci U S A* 111(11):4055-4060.
15. Wu CX, et al. (2019) Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics. *J Biol Chem*.
16. Huang X, et al. (2019) The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2. *Faseb J* 33(4):4814-4823.
17. Deng J, et al. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. *Proceedings of the National Academy of Sciences* 105(5):1499-1504
18. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, & Wittinghofer A (2008) Structure of the Roc-COR domain tandem of *C. tepidum*, a prokaryotic homologue of the human LRRK2 Parkinson kinase. *EMBO J* 27(17):2352.
19. Deyaert E, et al. (2017) A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover. *Nat Commun* 8(1):1008.
20. Huang X, et al. (2018) The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2. *FASEB J*:fj201802031R.

21. Bricogne G, Vonrhein C, Flensburg C, Schiltz M, & Paciorek W (2003) Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. *Acta Crystallogr D Biol Crystallogr* 59(Pt 11):2023-2030.
22. Adams PD, *et al.* (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 66(Pt 2):213-221.
23. Chavas LM, *et al.* (2007) Structure of the small GTPase Rab27b shows an unexpected swapped dimer. *Acta Crystallogr D Biol Crystallogr* 63(Pt 7):769-779.
24. Kukimoto-Niino M, *et al.* (2008) Structural basis for the exclusive specificity of Slac2-a/melanophilin for the Rab27 GTPases. *Structure* 16(10):1478-1490.
25. Gilsbach BK, *et al.* (2012) Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. *Proc Natl Acad Sci U S A* 109(26):10322-10327.
26. Gasper R, Meyer S, Gotthardt K, Sirajuddin M, & Wittinghofer A (2009) It takes two to tango: regulation of G proteins by dimerization. *Nat Rev Mol Cell Biol* 10(6):423-429.
27. Wittinghofer A & Pai EF (1991) The structure of Ras protein: a model for a universal molecular switch. *Trends Biochem Sci* 16(10):382-387.
28. Valencia A, Chardin P, Wittinghofer A, & Sander C (1991) The ras protein family: evolutionary tree and role of conserved amino acids. *Biochemistry* 30(19):4637-4648.
29. Pasqualato S, Menetrey J, Franco M, & Cherfils J (2001) The structural GDP/GTP cycle of human Arf6. *EMBO Rep* 2(3):234-238.
30. Taymans JM, *et al.* (2011) LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. *PLoS One* 6(8):e23207.
31. Lewis PA, *et al.* (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. *Biochemical and Biophysical Research Communications* 357(3):668-671.
32. Li Y, *et al.* (2009) The R1441C mutation alters the folding properties of the ROC domain of LRRK2. *Biochim Biophys Acta* 1792(12):1194-1197.
33. Li X, *et al.* (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. *J Neurochem* 103(1):238-247.
34. Flocco MM & Mowbray SL (1994) Planar stacking interactions of arginine and aromatic side-chains in proteins. *J Mol Biol* 235(2):709-717.
35. Guaitoli G, *et al.* (2016) Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts. *Proc Natl Acad Sci U S A* 113(30):E4357-4366.
36. Mills RD, *et al.* (2018) The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties. *J Neurochem* 147(3):409-428.
37. Zhang P, *et al.* (2019) Crystal structure of the WD40 domain dimer of LRRK2. *Proc Natl Acad Sci U S A* 116(5):1579-1584.
38. Brooks BR, *et al.* (2009) CHARMM: the biomolecular simulation program. *J Comput Chem* 30(10):1545-1614.
39. Phillips JC, *et al.* (2005) Scalable molecular dynamics with NAMD. *J Comput Chem* 26(16):1781-1802.
40. Otwinowski Z & Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol* 276:307-326.
41. Emsley P & Cowtan K (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60(Pt 12 Pt 1):2126-2132.
42. Emsley P, Lohkamp B, Scott WG, & Cowtan K (2010) Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* 66(Pt 4):486-501.
43. Winn MD, Murshudov GN, & Papiz MZ (2003) Macromolecular TLS refinement in REFMAC at moderate resolutions. *Methods Enzymol* 374:300-321.